Entrada Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
TRDA$4.69-4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share amounts)
| Common Stock · AdditionalPaid‑inCapital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balances at December 31, 2024 | 37,574,538 | $4 | $558,061 | $(43) | $(129,344) | $428,678 |
| Issuance of common stock upon exercise of stock options | 40,984 | — | 350 | — | — | 350 |
| Vesting of early exercised options | 1,676 | — | 14 | — | — | 14 |
| Vesting of restricted stock units | 325,085 | — | — | — | — | — |
| Stock‑based compensation | — | — | 5,087 | — | — | 5,087 |
| Other comprehensive income | — | — | — | 480 | — | 480 |
| Net loss | — | — | — | — | (17,349) | (17,349) |
| Balances at March 31, 2025 | 37,942,283 | $4 | $563,512 | $437 | $(146,693) | $417,260 |
| Issuance of common stock upon exercise of stock options | 12,106 | $— | $20 | $— | $— | $20 |
| Vesting of restricted stock units | 29,163 | — | — | — | — | — |
| Purchase of common stock under the employee stock purchase plan | 50,418 | — | 317 | — | — | 317 |
| Stock‑based compensation | — | — | 5,048 | — | — | 5,048 |
| Other comprehensive loss | — | — | — | (37) | — | (37) |
| Net loss | — | — | — | — | (43,103) | (43,103) |
| Balances at June 30, 2025 | 38,033,970 | $4 | $568,897 | $400 | $(189,796) | $379,505 |
| Common Stock · AdditionalPaid‑inCapital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders’ Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balances at December 31, 2023 | 33,437,296 | $3 | $437,132 | $195 | $(194,970) | $242,360 |
| Issuance of common stock upon exercise of stock options | 30,888 | — | 206 | — | — | 206 |
| Vesting of early exercised options | 3,411 | — | 13 | — | — | 13 |
| Vesting of restricted stock units | 132,458 | — | — | — | — | — |
| Stock‑based compensation | — | — | 3,733 | — | — | 3,733 |
| Other comprehensive loss | — | — | — | (441) | — | (441) |
| Net income | — | — | — | — | 23,496 | 23,496 |
| Balances at March 31, 2024 | 33,604,053 | $3 | $441,084 | $(246) | $(171,474) | $269,367 |
| Issuance of common stock upon exercise of stock options | 166,155 | $— | $1,104 | $— | $— | $1,104 |
| Vesting of early exercised options | 3,411 | — | 13 | — | — | 13 |
| Vesting of restricted stock units | 11,490 | — | — | — | — | — |
| Purchase of common stock under the employee stock purchase plan | 20,384 | — | 263 | — | — | 263 |
| Issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs of $392 | 3,367,003 | 1 | 99,607 | — | — | 99,608 |
| Stock‑based compensation | — | — | 4,622 | — | — | 4,622 |
| Other comprehensive loss | — | — | — | (83) | — | (83) |
| Net income | — | — | — | — | 55,031 | 55,031 |
| Balances at June 30, 2024 | 37,172,496 | $4 | $546,693 | $(329) | $(116,443) | $429,925 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.